Related Experiment Videos
Hypertension and renal disease
1Division of Nephrology, University of Rome La Sapienza, Rome, Italy.
Renal Failure
|January 1, 1993
Summary
Chronic renal disease often causes hypertension. Enalapril effectively lowers blood pressure and slows kidney disease progression in IgA nephropathy patients.
Area of Science:
- Nephrology
- Hypertension Research
- Internal Medicine
Background:
- Chronic renal parenchymal disease is a leading cause of secondary hypertension, affecting up to 85% of end-stage renal disease patients.
- Traditionally, hypertension was thought to cause renal damage; however, increased intraglomerular pressure due to impaired autoregulation is now emphasized.
- Inconsistent findings on slowing renal damage with antihypertensive therapy may stem from inadequate BP monitoring or insufficient BP control targets.
Purpose of the Study:
- To investigate the relationship between hypertension and chronic kidney disease.
- To evaluate the efficacy of enalapril in managing hypertension and IgA nephropathy.
Main Methods:
- Retrospective analysis of serum creatinine levels in hypertensive versus normotensive nephropathic patients.
- Prospective trial assessing enalapril's antihypertensive efficacy and effect on disease progression in IgA nephropathy.
Main Results:
- Hypertensive nephropathic patients exhibited higher serum creatinine levels compared to normotensive individuals.
- Enalapril demonstrated effectiveness as an antihypertensive agent in patients with IgA nephropathy.
- Enalapril treatment was associated with amelioration of IgA nephropathy progression.
Conclusions:
- Hypertension is a significant factor in chronic renal parenchymal disease progression.
- Enalapril is a beneficial treatment for hypertensive patients with IgA nephropathy, impacting both blood pressure and disease course.